Traws Pharma, Inc. (NASDAQ:TRAW) Short Interest Update

Traws Pharma, Inc. (NASDAQ:TRAW) was the target of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 10,400 shares, an increase of 40.5% from the October 31st total of 7,400 shares. Based on an average trading volume of 11,000 shares, the short-interest ratio is currently 0.9 days. Approximately 0.5% of the company’s shares are short sold.

Traws Pharma Trading Down 3.4 %

Traws Pharma stock traded down $0.16 during trading hours on Friday, reaching $4.58. The stock had a trading volume of 3,915 shares, compared to its average volume of 5,938. The stock has a market cap of $13.88 million, a PE ratio of -0.03 and a beta of 1.41. Traws Pharma has a 52 week low of $4.06 and a 52 week high of $27.50. The company’s fifty day simple moving average is $5.18.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.